According to the IMARC Group, the prediabetes market reached a value of US$ 23.8 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach US$ 48.7 Billion by 2035, exhibiting a growth rate (CAGR) of 6.72% during 2025-2035. This can be attributed to the growing use of agonists of the glucagon-like peptide-1 receptor to treat the illness by boosting insulin production, encouraging weight loss, and improving quality of life.

Prediabetes refers to a medical condition defined by higher-than-normal blood sugar levels but not high enough to be categorized as type 2 diabetes. The prediabetes market is experiencing substantial growth due to several key factors. Primarily, the market is propelled by the increasing prevalence of prediabetes, driven by rising obesity rates, sedentary lifestyles, and poor dietary habits. Additionally, advancements in diagnostic tools, such as continuous glucose monitors and advanced blood tests like HbA1c assays, are enabling earlier and more accurate detection of prediabetes, fostering timely intervention. Another factor driving the growth of the prediabetes market is the increasing use of lifestyle modification programs, such as diet, exercise, and weight control, as first-line treatments for prediabetes. Furthermore, pharmaceutical companies are focusing on developing and promoting medications such as metformin and newer antidiabetic agents, which have been shown to manage blood sugar levels in prediabetic patients. Governmental and non-governmental organizations are playing a crucial role by funding awareness campaigns, promoting lifestyle changes, and supporting community-based diabetes prevention programs.

Request for a sample of this report: https://www.imarcgroup.com/prediabetes-market/requestsample

Countries Covered:

• United States

• Germany

• France

• United Kingdom

• Italy

• Spain

• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario

• Historical, current, and future performance of the Prediabetes Market

• Historical, current, and future performance of various therapeutic categories in the market

• Sales of various drugs across the Prediabetes Market

• Reimbursement scenario in the market

• In-market and pipeline drugs

This report also provides a detailed analysis of the current Prediabetes Market drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview

• Mechanism of Action

• Regulatory Status

• Clinical Trial Results

• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview

• Mechanism of action

• Regulatory status

• Clinical trial results

• Drug uptake and market performance

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/prediabetes-market

Competitive Landscape with key players:

The competitive landscape of the Prediabetes Market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Aphaia Pharma

2. AstraZeneca

3. Celgene, Bristol-Myers Squibb